SUBSCRIBERS

Biotech firm shows the way onto the global stage

InvitroCue debuts on the ASX just four years after its birth; sales growth has doubled and is 'sustainable', says founder

Published Wed, Jan 27, 2016 · 09:50 PM

Singapore

SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage.

The biotech firm, a spin-off from the Agency for Science, Technology and Research (A*Star), helps drug-makers determine which vaccines, products or devices are safe to use in humans - even before tests are conducted to determine if they work.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes